4.3 Article

STN versus GPi deep brain stimulation for dyskinesia improvement in advanced Parkinson's disease: A meta-analysis of randomized controlled trials

期刊

CLINICAL NEUROLOGY AND NEUROSURGERY
卷 201, 期 -, 页码 -

出版社

ELSEVIER
DOI: 10.1016/j.clineuro.2020.106450

关键词

Deep brain stimulation; Subthalamic nucleus; Globus pallidus internus; Parkinson's disease; Dyskinesia

资金

  1. National Natural Science Foundation of China [81471676, 31300137]
  2. Chongqing Natural Science Foundation of China [cstc2014jcyjA10050]
  3. Chongqing Health Bureau Traditional Chinese Medicine Science Foundation of China [ZY20132103]
  4. Chongqing Health Bureau Science Foundation of China [2012-2-065]

向作者/读者索取更多资源

Both STN and GPi-DBS were equally effective in improving motor dysfunction in patients with APD. However, STN-DBS showed superiority in reducing medication usage, while GPi-DBS may lead to less dyskinesia and improved activities of daily living. Further studies comparing adverse events and quality of life between these two targets are needed.
Background: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) and the globus pallidus internus (GPi) are currently the most common and effective surgical targets for advanced Parkinson's disease (APD). Herein, we conducted a meta-analysis to evaluate the comprehensive efficacy of STN-DBS and GPi-DBS in patients with APD. Methods: We conducted a systematic search for relevant articles written in English in the Cochrane Library, PubMed, and EMBASE databases through January 2020. Studies comparing the efficacy and clinical outcomes of GPi-DBS and STN-DBS for APD were included and analyzed. Results: Ten eligible trials with a total of 857 patients were included in this meta-analysis. The results showed no significant difference between the STN-DBS and GPi-DBS groups in Unified Parkinson's Disease Rating Scale (UPDRS) III scores during the on and off-medication phases(SMD, 0.1; 95 % CI,-0.04 to 0.25; p = 0.17, on-med), (SMD, -0.12;95 % CI-0.37 to 0.13, p = 0.33,off-med). Dyskinesia scores and the activities of daily living (ADLs) scores during the on-medication phase showed significant differences in favor of GPi stimulation (SMD, 0.16; 95 % CI, 0.01-0.32; P < 0.05)/(SMD, 0.18; 95 % CI, 0.01-0.34; P < 0.05). The ADLs score during the off-medication phase showed no significant difference between the STN-DBS and GPi-DBS groups (SMD,-0.11; 95 % CI, 0.32-0.11; P = 0.33). The LED showed significant differences in favor of STN stimulation (SMD, -0.57; 95 % CI, 0.74-0.40; P < 0.00001). Conclusions: Both STN and GPi-DBS were equally effective in improving motor dysfunction. STN-DBS was superior for medication reduction, whereas GPi-DBS perhaps led to less dyskinesia and improved the postoperative ADLs (on-medication) in APD patients. Hence, the goals of DBS can be important in the target selection. More studies comparing the adverse events and quality of life between the two targets are needed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据